Monoaminergic agents modulate antidepressant-like effect caused by diphenyl diselenide in rats.
In this study, the antidepressant-like effect caused by diphenyl diselenide on rat forced swimming test (FST) was investigated. The involvement of the monoaminergic system in the antidepressant-like effect was also evaluated. Diphenyl diselenide (0.1-30 mg/kg), given by oral route (p.o.), 30 min earlier, reduced the immobility time in the FST, without accompanying changes in ambulation when assessed in an open field. The anti-immobility effect of diphenyl diselenide (1 mg/kg, p.o.) on the FST was prevented by pretreatment of rats with p-chlorophenylalanine methyl ester (PCPA; 100 mg/kg, i.p., an inhibitor of serotonin synthesis, given once a day, for 3 consecutive days), WAY100635 (0.1 mg/kg, s.c., a selective 5-HT(1A) receptor antagonist), ketanserin (1 mg/kg, i.p., a 5-HT(2A)/(2C) receptor antagonist), ondasentron (1 mg/kg, i.p., a 5-HT(3) receptor antagonist), haloperidol (1 mg/kg, i.p., a D(1), D(2) and D(3) receptor antagonist), SCH233390 (0.05 mg/kg, s.c., a D(1) receptor antagonist), sulpiride (50 mg/kg, i.p., a D(2) receptor antagonist), prazosin (1 mg/kg, i.p., an alpha(1)-adrenoceptor antagonist), yohimbine (1 mg/kg, i.p., an alpha(2)-adrenoceptor antagonist). However, the anti-immobility effect caused by diphenyl diselenide (1 mg/kg, p.o.) on the FST was not affected by pretreatment with propanolol (2 mg/kg, i.p., a beta-adrenoceptor antagonist). Furthermore, monoamine oxidase (MAO) activity was inhibited (39%) in the animals treated with diphenyl diselenide (30 mg/kg, p.o.) when compared to the control group. Taken together these data demonstrated that the antidepressant-like effect caused by diphenyl diselenide seems to be mediated by involvement of the central monoaminergic system.
Savegnago
Lucielli
L
Laboratório de Síntese, Reatividade e Avaliação Farmacológica e Toxicológica de Organocalcogênios, Centro de Ciências Naturais e Exatas, Universidade Federal de Santa Maria, 97105-900, Santa Maria, RS, Brazil.
Jesse
Cristiano R
CR
Pinto
Larissa G
LG
Rocha
Joao B T
JB
Nogueira
Cristina W
CW
Zeni
Gilson
G
D000284:Administration, Oral; D000704:Analysis of Variance; D000818:Animals; D000928:Antidepressive Agents / Q000008:administration & dosage*; D001522:Behavior, Animal / Q000187:drug effects; D001555:Benzene Derivatives / Q000008:administration & dosage*; D015306:Biogenic Monoamines / Q000378:metabolism*; D001921:Brain / Q000187:drug effects; D003863:Depression / Q000517:prevention & control*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005106:Exploratory Behavior / Q000187:drug effects; D010134:Fenclonine / Q000031:analogs & derivatives / Q000494:pharmacology; D046352:Freezing Reaction, Cataleptic / Q000187:drug effects*; D008297:Male; D018377:Neurotransmitter Agents / Q000145:classification / Q000494:pharmacology*; D016566:Organoselenium Compounds / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar; D013550:Swimming; D013997:Time Factors
D000928:Antidepressive Agents; D001555:Benzene Derivatives; D015306:Biogenic Monoamines; D018377:Neurotransmitter Agents; D016566:Organoselenium Compounds; C061132:diphenyldiselenide; C020261:4-chlorophenylalanine methyl ester; D010134:Fenclonine